Aurobindo Pharma Clarifies USFDA Inspection at Telangana Unit VII

Regulatory & Legal View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹1181.00

prior close

₹1156.80

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.5%-1.6% vs market

Pharmaceuticals peers, median of 156sector+0.2%-1.2% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty Midcap 150 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.2

15m

-0.2

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+0.5-1.6+0.2-1.2

Next day

-0.8-1.0+0.3-0.7-0.1

-2.0-0.6-1.5-0.7-1.3

-2.7-0.7-2.0-0.8-1.9

-1.5-1.0-0.5-1.4-0.2

+2.9-0.4+3.3-1.1+4.0

+3.3-0.9+4.2-2.0+5.3

15d

+10.9-5.7+16.6-4.5+15.5

+7.4-5.9+13.2-5.3+12.6

+15.6-0.1+15.7+0.8+14.8

+27.0+0.7+26.3+3.5+23.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma responded to NSE's clarification request about a media report of its shares falling after USFDA flagged quality concerns at its Telangana plant. The company said it will reply to the US FDA within stipulated timelines regarding its Unit VII inspection completed on February 10, 2026. It stated there is no further material event requiring disclosure under SEBI LODR rules and that regulatory inspections are routine business operations.

Likely market impact

Stock may stay volatile as USFDA response is awaited; company says nothing new to disclose and views inspections as routine.